Centalun was developed by Boehringer Ingelheim in 1962[1] and is a
psycholeptic drug with
hypnotic and
sedative effects, via
allosteric agonism of the
GABAA receptor.[2] It was previously used for sedation in medical procedures such as surgery,[3] orthopedics[4] and gynecology,[5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the
CSA and therefore remains unregulated as a drug of abuse.
References
^BE 618130, "Procédé pour l'obtention d'alkinediols"
^Janke W, Glathe H (June 1964). "[Experimental Studies on the Psychic Effect of Sedatives Under Normal and Stress Conditions]". Psychologische Forschung (in German). 27: 377–402.
doi:
10.1007/bf00421338.
PMID14233519.
S2CID144088161.
^Monecke K (July 1964). "[Pre- and Postoperative Use of Centalun in Surgery]". Deutsches Medizinisches Journal (in German). 15: 470–1.
PMID14238754.
^Bruckschen E (July 1964). "[Sedative Therapy with Centalun in Orthopedics]". Deutsches Medizinisches Journal (in German). 15: 493–4.
PMID14243120.
^Gerlach W, Gerlach E (March 1964). "[Experiences with Centalun in Obstetrical and Gynecological Patients]". Medizinische Monatsschrift (in German). 18: 131–3.
PMID14193290.